🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-522033-64-00
Ongoing Phase I

A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor

2025-522033-64-00 · tracked via the Priya Life Science EU tracker
Sponsor
Ajax Therapeutics Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
09/02/2026
Enrollment target
20
Sites
Italy, France, Spain

Condition studied

Myelofibrosis

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522033-64-00 on CTIS ↗ ← All trials in the EU